Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Gross Profit: 2019-2025

Historic Gross Profit for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $11.2 million.

  • C4 Therapeutics' Gross Profit fell 26.90% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of $35.6 million for FY2024, which is 71.44% up from last year.
  • C4 Therapeutics' Gross Profit amounted to $11.2 million in Q3 2025, which was up 73.76% from $6.5 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Gross Profit high stood at $20.1 million for Q4 2021, and its period low was $2.7 million during Q2 2023.
  • Moreover, its 3-year median value for Gross Profit was $6.5 million (2025), whereas its average is $7.4 million.
  • Per our database at Business Quant, C4 Therapeutics' Gross Profit tumbled by 85.79% in 2022 and then skyrocketed by 350.68% in 2024.
  • C4 Therapeutics' Gross Profit (Quarterly) stood at $20.1 million in 2021, then plummeted by 85.79% to $2.9 million in 2022, then rose by 14.26% to $3.3 million in 2023, then spiked by 58.75% to $5.2 million in 2024, then decreased by 26.90% to $11.2 million in 2025.
  • Its Gross Profit stands at $11.2 million for Q3 2025, versus $6.5 million for Q2 2025 and $7.2 million for Q1 2025.